AN Ventures builds companies out of under-commercialized Japanese life science research, moving that science into top global biotech hubs instead of just funding startups to stay in Japan, and it does this with backing from both the Japanese government and ARCH Venture Partners, plus close ties to organizations like AMED and Fast Track Initiative. Rather than only writing checks, the firm actively builds companies with experienced global management teams, runs the S2S Japan program to connect Japanese researchers with entrepreneurs and global investors, and partners with pharma companies like Shionogi to combine R&D insight with company-creation support for scientists whose research might otherwise stay stuck in Japan.